Cellectis (NASDAQ:CLLS) Issues Earnings Results, Misses Estimates By $0.43 EPS

Cellectis (NASDAQ:CLLS) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.43), FiscalAI reports. The firm had revenue of $5.44 million for the quarter, compared to analyst estimates of $15.61 million. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.

Cellectis Trading Down 3.6%

CLLS stock traded down $0.05 during trading on Thursday, hitting $1.33. The company had a trading volume of 40,281 shares, compared to its average volume of 59,406. The business has a 50-day moving average of $1.53 and a 200-day moving average of $2.95. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.61. Cellectis has a one year low of $0.88 and a one year high of $5.45. The stock has a market cap of $133.45 million, a PE ratio of -2.05 and a beta of 3.21.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Weiss Ratings upgraded Cellectis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. Citizens Jmp downgraded Cellectis from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 15th. Robert W. Baird decreased their target price on shares of Cellectis from $10.00 to $8.00 and set an “outperform” rating on the stock in a report on Tuesday, September 15th. Wells Fargo & Company lowered their price target on Cellectis from $4.00 to $3.00 and set an “equal weight” rating for the company in a report on Tuesday, September 15th. Finally, Barclays cut shares of Cellectis from an “overweight” rating to an “underweight” rating and lowered their price objective for the stock from $9.00 to $1.30 in a research report on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Cellectis presently has a consensus rating of “Hold” and an average target price of $5.46.

About Cellectis

Cellectis is a biotechnology company focused on developing gene-edited cell and gene therapies, with an emphasis on treatments for cancer. Founded in France in 1999, the company operates in France and the United States. Its research centers on TALEN gene-editing technology, which it uses to modify cells for potential therapeutic applications. Cellectis is developing allogeneic CAR T-cell therapies made from donor T cells, an approach intended to create treatments that can be prepared for use by multiple patients rather than made individually for each patient.